A randomized, open label study of the efficacy of prophylactic 24-h low-dose landiolol for atrial fibrillation in transthoracic esophagectomy

作者：Yoshida Takahiro^*; Furukita Yoshihito; Yamamoto Yota; Nishino Takeshi; Inoue Seiya; Morimoto Masami; Okumura Kazumasa; Toba Hiroaki; Yoshida Mitsuteru; Takizawa Hiromitsu; Tangoku Akira

来源：Esophagus, 2017, 14(1): 97-103.

DOI：10.1007/s10388-016-0553-5

• Landiolol
• Prevention
• Atrial fibrillation
• Esophagectomy
• Tachycardia

Purpose Atrial fibrillation (Af) is one of the common cardiovascular complications after esophagectomy. Lowdose landiolol prevented postoperative Af after administration was previously reported. We evaluated the preventive effects and safety of landiolol, a beta 1-selective blocker, on postoperative tachycardia (>= 120 bpm) or Af after esophagectomy. Patients and methods Eighty consecutive patients scheduled for esophagectomy at our institute between July 2009 and March 2014. Patients were randomly assigned to a landiolol or control group. Landiolol was administrated at 5 mu g/kg/min for 24 h after induction of anesthesia. Electrocardiography was monitored continuously for 2 days after surgery. Results There were no significant differences in patient background between the control group (n = 40) and the landiolol group (n = 39) except for one patient with preoperative Af. Af was identified in only one patient in the control group, and the onset was on the second postoperative day. Overall, the incidence of Af was 1.3 % (1/79). Incidences of tachycardia were 12.5 and 12.8 % in the control group and the landiolol group, respectively. No adverse event was identified. Conclusions This study could not show the superiority of prophylactic 24-h low-dose landiolol for postoperative Af in transthoracic esophagectomy. High-risk patients might be candidates for preventive landiolol.

• 出版日期2017-1